Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2026-01-07 Regulatory Filings
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance related to dematerialisation of securities for the quarter ended 31st December 2025. It is addressed to stock exchanges' compliance departments and is a compliance certificate rather than a financial report or announcement of financial results. The document length is 3753 characters, which is relatively short and primarily serves as a regulatory compliance certificate. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and regulatory announcements that do not fit other specific categories.
2026-01-07 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window for insiders due to upcoming financial results. It references SEBI regulations on insider trading and specifies the trading window closure period around the announcement of quarterly and nine-month financial results. The document does not contain any financial data or results itself, nor does it present a report. It is a compliance notification related to insider trading restrictions ahead of financial disclosures. Given its nature as a regulatory compliance announcement and not a financial report or earnings release, it fits best under Regulatory Filings (RNS). The document length is short (1853 characters), and it is clearly an announcement rather than a report or detailed filing.
2025-12-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the schedule of an Investors/Analysts Meet. It references compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events or information. The document does not contain any financial data, report content, or detailed analysis. It is an announcement of a meeting schedule rather than a report or transcript. The length is only 1739 characters, indicating it is a brief notice. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the schedule of an Investors/Analysts Meet. It references compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure obligations. The document does not contain any financial data, report content, or detailed analysis. It is an announcement of a meeting schedule rather than a report or detailed filing. The document length is only 2137 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-08 English
Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for a new pharmaceutical product by ZIM Laboratories Limited. It is addressed to stock exchanges and includes details about the product, its therapeutic indication, and strategic significance. The document does not contain financial data, earnings, management discussion, or any detailed report content. It is a corporate announcement about a regulatory approval event, not a financial report or filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-12-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Q2 and H1 FY 2026 of ZIM Laboratories Limited. It includes management discussion of financial results, business outlook, operational updates, and a Q&A session with analysts. The text explicitly mentions it is a transcript of the earnings call, with detailed financial figures, segment performance, and forward-looking statements. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters, contains substantive financial data and management commentary, and is not merely an announcement or summary. Therefore, the correct classification is CT with high confidence.
2025-11-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.